MedTrace Logo

Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET"

NCT05276999 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66123

Last updated 2024-06-04

No results posted yet for this study

Summary

The primary objective of this study is to determine the impact of a pragmatic RHD primary prevention program in Uganda.

The secondary Objective are as follow:

1. To improve guideline-based care for sore throat through frontline healthcare provider education on clinical decision rules and guideline-based primary prevention.
2. To increase health seeking behavior for sore throat thorough a multifaceted community awareness campaign.

Conditions

  • Rheumatic Heart Disease

Interventions

OTHER

Healthcare provider education

Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis

OTHER

Community Awareness campaign

A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.

Sponsors & Collaborators

  • Uganda Heart Institute

    collaborator OTHER

  • Children's National Research Institute

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Andrea Z Beaton · Cincinnati Chidren's hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05276999 on ClinicalTrials.gov